The first look at Turning Point’s TPX-0022 shows signs of activity beyond cMet inhibitors’ proven use in lung cancer.
The German group hopes that boosting its presence in gene therapy will drive growth of its pharma business.
A patient death overshadowed the first data from a human trial of the company’s allogeneic Car-T therapy CTX110.
A mid-stage clinical failure raises more doubts about Galapagos’s pipeline and the wisdom of Gilead’s $5bn deal last year.
The pandemic remains the dominant storyline for drug stocks at the nine-month mark, with Vertex and Horizon rare non-Covid-related risers.
Few signs of a tightening regulatory climate can be found in approval numbers for 2020 – but some big decisions are still pending.
The company’s EGFR and cMet targeted bispecific has generated early but encouraging signals in lung cancer – however, J&J faces stiff competition.